FDA Checks Overdue for Nearly 2,000 Drug Plants Due to COVID Delays
As the COVID pandemic reshapes the landscape of pharmaceutical oversight, FDA checks on nearly 2,000 drug plants remain significantly overdue. Federal regulators responsible for ensuring safety within the U.S. drug supply have battled to return to inspection norms established before COVID, which has introduced critical risks to drug quality. Listening to the call for action is more crucial than ever as these delays threaten patient safety across the nation.
Regulatory gaps emphasize the need for advanced measures to expedite inspections and uphold stringent safety standards. Without prompt intervention, the repercussions could be severe, influencing both healthcare accessibility and patient outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.